BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16040085)

  • 1. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy.
    Epstein JI; Sanderson H; Carter HB; Scharfstein DO
    Urology; 2005 Aug; 66(2):356-60. PubMed ID: 16040085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer.
    Loeb S; Roehl KA; Thaxton CS; Catalona WJ
    Urology; 2008 Jul; 72(1):143-7. PubMed ID: 18436287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.
    Boccon-Gibod LM; Dumonceau O; Toublanc M; Ravery V; Boccon-Gibod LA
    Eur Urol; 2005 Dec; 48(6):895-9. PubMed ID: 16125298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population?
    Anast JW; Andriole GL; Bismar TA; Yan Y; Humphrey PA
    Urology; 2004 Sep; 64(3):544-50. PubMed ID: 15351590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management.
    Ochiai A; Troncoso P; Chen ME; Lloreta J; Babaian RJ
    J Urol; 2005 Dec; 174(6):2164-8, discussion 2168. PubMed ID: 16280756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis.
    Cupp MR; Bostwick DG; Myers RP; Oesterling JE
    J Urol; 1995 May; 153(5):1543-8. PubMed ID: 7714976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively?
    Rubin MA; Mucci NR; Manley S; Sanda M; Cushenberry E; Strawderman M; Montie JE; Bassily NH
    J Urol; 2001 Jan; 165(1):114-8. PubMed ID: 11125378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapy.
    Falzarano SM; Zhou M; Hernandez AV; Moussa AS; Jones JS; Magi-Galluzzi C
    Urology; 2010 Sep; 76(3):682-7. PubMed ID: 20206973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved accuracy for predicting the Gleason score of prostate cancer by increasing the number of transrectal biopsy cores.
    Miyake H; Kurahashi T; Takenaka A; Hara I; Fujisawa M
    Urol Int; 2007; 79(4):302-6. PubMed ID: 18025846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
    Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K
    Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?
    Chan TY; Chan DY; Stutzman KL; Epstein JI
    J Urol; 2001 Dec; 166(6):2181-4. PubMed ID: 11696731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological features after radical prostatectomy in potential candidates for active monitoring.
    Griffin CR; Yu X; Loeb S; Desireddi VN; Han M; Graif T; Catalona WJ
    J Urol; 2007 Sep; 178(3 Pt 1):860-3; discussion 863. PubMed ID: 17631347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens.
    Divrik RT; Eroglu A; Sahin A; Zorlu F; Ozen H
    Urol Oncol; 2007; 25(5):376-82. PubMed ID: 17826653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
    Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
    J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased detection of clinically significant prostate cancer by additional sampling from the anterior lateral horns of the peripheral zone in combination with the standard sextant biopsy.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2004 Jun; 11(6):402-6. PubMed ID: 15157210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance.
    Ochiai A; Trpkov K; Yilmaz A; Donnelly B; Babaian RJ
    J Urol; 2007 Mar; 177(3):907-10. PubMed ID: 17296373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.